Holen Sie sich die Stockscreener-App
6.44
7.69%
0.46
Vorhandelsmarkt:
6.50
0.06
+0.93%
Tevogen Bio Holdings Inc Aktie (TVGN) Neueste Nachrichten
Aug Outlook: What is Tevogen Bio Holdings Incs valuation compared to sectorPortfolio Update Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Forecast Cut: Is Tevogen Bio Holdings Inc stock good for income investors2026 PreEarnings & Expert Approved Trade Ideas - baoquankhu1.vn
Sentiment Watch: What is Tevogen Bio Holdings Incs valuation compared to sector2026 Opening Moves & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Retail Trends: Is Tevogen Bio Holdings Inc Equity Warrant in accumulation or distribution phase2026 Institutional Moves & Low Risk Entry Point Tips - baoquankhu1.vn
Quarterly Risk: Whats the outlook for Tevogen Bio Holdings Incs sector2026 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn
Loss Report: Is VCTR a potential multi baggerDollar Strength & Daily Stock Trend Reports - baoquankhu1.vn
TVGN Should I Buy - Intellectia AI
Buyout Rumor: Should you avoid Tevogen Bio Holdings Inc stock right now2026 Retail & Daily Growth Stock Tips - baoquankhu1.vn
Tevogen Bio (NASDAQ: TVGN) maps T-cell therapy and Long COVID push - Stock Titan
Tevogen Bio Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aug Sectors: Is Tevogen Bio Holdings Inc Equity Warrant undervalued by DCF analysis2026 Action & Long Hold Capital Preservation Tips - baoquankhu1.vn
Tevogen Bio Holdings Inc.Common Stock (NQ: TVGN - FinancialContent
Aug Macro: Can Tevogen Bio Holdings Inc Equity Warrant maintain its current growth rate2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Volatility Watch: Is Tevogen Bio Holdings Inc stock a good pick for beginners2026 Trade Ideas & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Loss Report: Is Tevogen Bio Holdings Inc Equity Warrant stock heavily shortedMarket Trend Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Tevogen Bio Regains Nasdaq Compliance After Reverse Split - The Globe and Mail
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth - Bitget
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and ... - Bluefield Daily Telegraph
Tevogen Bio Holdings Inc. Files Form 8-K on NASDAQ: Company Details and Key Information for March 2026 - Minichart
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement - Taiwan News
Tevogen Regains Compliance With Nasdaq Minimum Bid Price Requirement - 富途牛牛
Tevogen Bio regains Nasdaq compliance following reverse stock split By Investing.com - Investing.com India
Tevogen Bio regains Nasdaq compliance following reverse stock split - Investing.com
Tevogen Bio Holdings regains Nasdaq bid-price compliance after 1-for-50 reverse split - TradingView
Nasdaq restores TVGN listing after 1-for-50 reverse split (TVGN) - Stock Titan
Tevogen Bio (TVGN) restores Nasdaq bid-price compliance after 1-for-50 reverse split - Stock Titan
Tevogen regains compliance with Nasdaq minimum bid price requirement - TipRanks
Tevogen Bio Regains Compliance With Nasdaq Listing Rule - MarketScreener
Tevogen Bio Holdings Regains Compliance with Nasdaq Listing Requirements - Quiver Quantitative
Investment Report: Is Tevogen Bio Holdings Inc stock good for income investors2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Tevogen Bio Holdings Inc expected to post a loss of $2.00 a shareEarnings Preview - TradingView
Market Pulse: Why is Tevogen Bio Holdings Inc Equity Warrant stock going upWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Revenue Check: Why is Tevogen Bio Holdings Inc Equity Warrant stock going up - baoquankhu1.vn
TVGN Technical Analysis & Stock Price Forecast - Intellectia AI
Tevogen Bio Holdings Inc. Announces CIO Mittul Mehta to Speak at Microsoft Fabric Community Conference 2026 on Data Engineering and AI - Quiver Quantitative
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026) - Finviz
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community ... - Caledonian Record
Microsoft FabCon puts Tevogen AI chief on two data engineering panels - Stock Titan
Neal Flomenberg sells Tevogen Bio Holdings (TVGN) shares for $6.6k - Investing.com
Neal Flomenberg sells Tevogen Bio Holdings (TVGN) shares for $6.6k By Investing.com - Investing.com South Africa
Tevogen Bio (TVGN) officer sells 972 shares to cover tax obligations - Stock Titan
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure - The Manila Times
Tevogen reports performance advancements for Tevogen.AI platform - TipRanks
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization - The Globe and Mail
Tevogen Bio Advances AI Drug Development Platform with Improved Predictive Accuracy for Target Identification - Quiver Quantitative
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics ... - bdtonline.com
Tevogen.AI Reports Advancements in PredicTcell Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure - 富途牛牛
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform - Finviz
Wall Street Recap: Is Tevogen Bio Holdings Inc Equity Warrant undervalued by DCF analysisEarnings Overview Report & Real-Time Market Trend Scan - baoquankhu1.vn
Tevogen Bio Holdings Inc. is considering the acquisition of Sciometrix and Clinicus platforms to enhance its monitoring capabilities for Long Covid. - Bitget
Tevogen Bio Accelerates Development of TVGN 489 for Long COVID with New Leadership and Strategic Initiatives - Quiver Quantitative
Long COVID ‘clinical emergency’: Tevogen develops T-cell therapy for 65% of U.S. - Stock Titan
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):